Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Operating expenses: | ||||||
| Research and development | $ 149,638 | $ 43,141 | $ 288,642 | $ 283,266 | $ 977,768 | $ 2,013,762 |
| General and administrative | 866,932 | 447,360 | 1,464,570 | 1,003,941 | 933,742 | 1,612,685 |
| Compensation Expense | 5,110 | 46,723 | 18,710 | 69,123 | 178,382 | 582,862 |
| Total operating expenses | 1,021,680 | 537,224 | 1,771,922 | 1,356,330 | 2,134,112 | 4,214,434 |
| Loss from operations | (1,021,680) | (537,224) | (1,771,922) | (1,356,330) | (2,134,112) | (4,214,434) |
| Other expenses: | ||||||
| Interest expense | (39,477) | (54,480) | (106,698) | (106,515) | (207,117) | (236,577) |
| Amortization of IP | (2,188) | (911) | (2,702) | (1,822) | (3,644) | |
| Debt discount amortization | (312,431) | (77,031) | ||||
| Debt discount amortization and issuance of warrants | (348,637) | (41,425) | (348,637) | (132,759) | ||
| Total other income (expenses) | (390,302) | (96,816) | (458,037) | (241,096) | (523,192) | (313,608) |
| Net loss before provision for income taxes | (1,411,982) | (634,040) | (2,229,959) | (1,597,426) | (2,657,304) | (4,528,042) |
| Provision for income taxes | ||||||
| NET LOSS | (1,411,982) | (634,040) | (2,229,959) | (1,597,426) | (2,657,304) | (4,528,042) |
| Net loss attributable to the non-controlling interest | 764 | 11,691 | 33,658 | 62,807 | 193,372 | 496,297 |
| NET LOSS ATTRIBUTABLE TO BIOXYTRAN | $ (1,411,218) | $ (622,349) | $ (2,196,301) | $ (1,534,619) | $ (2,463,932) | $ (4,031,745) |
| Loss per Common share, basic | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.01) | $ (0.02) | $ (0.04) |
| Loss per Common share, diluted | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.01) | $ (0.02) | $ (0.04) |
| Weighted average number of Common shares outstanding, basic | 128,804,789 | 110,840,998 | 126,224,323 | 110,840,998 | 115,139,380 | 106,252,116 |
| Weighted average number of Common shares outstanding, diluted | 128,804,789 | 110,840,998 | 126,224,323 | 110,840,998 | 115,139,380 | 106,252,116 |
| Related Party [Member] | ||||||
| Operating expenses: | ||||||
| General and administrative related party | $ 44,220 | $ 5,125 | ||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|